Fig. 2: High-throughput sequencing analysis of differential LCN2 expression in a vitamin D-cisplatin chemotherapy model. | Cell Death & Disease

Fig. 2: High-throughput sequencing analysis of differential LCN2 expression in a vitamin D-cisplatin chemotherapy model.

From: Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3

Fig. 2

a Heatmap of RNA-seq data in CAL-27 cells treated with PBS (control), vitamin D (Vit D), cisplatin (Cis) and vitamin D plus cisplatin (Cis + Vit D); b Gene Ontology (GO) analysis of differentially expressed genes in CAL-27 cells treated with vitamin D; c GO analysis of differentially expressed genes in CAL-27 cells treated with cisplatin; d qPCR detection of changes in the mRNA expression levels of LCN2 during vitamin D-cisplatin treatment; e Immunoblot analysis of the changes in LCN2 protein expression during vitamin D-cisplatin treatment; f Immunohistochemistry was used to detect the expression of LCN2 in the four groups of tumour tissues in nude mouse xenografts (scale bar: 20 μm); g Gel image of LCN2 promoter methylation and unmethylation.

Back to article page